Huadong Medicine's Subsidiary Receives FDA Clearance to Initiate Clinical Trials of DR10624 Injection for Severe Hypertriglyceridemia in the U.S.

Gelonghui October 21 | Huadong Medicine (000963.SZ) announced that its controlling subsidiary, Doer Biologics, has received notification from the U.S. FDA approving the clinical trial application for DR10624 injection. The clinical trial for the indication of severe hypertriglyceridemia can now be conducted in the United States. DR10624 is a globally pioneering long-acting trispecific agonist independently developed by Doer Biologics. It has previously completed Phase II clinical research with positive topline results. The development of this drug carries uncertainties and will not have a significant impact on the company’s recent performance.